Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study

被引:0
|
作者
Alessandro Maria Vannucchi
Srdan Verstovsek
Paola Guglielmelli
Martin Griesshammer
Timothy C. Burn
Ahmad Naim
Dilan Paranagama
Mahtab Marker
Brian Gadbaw
Jean-Jacques Kiladjian
机构
[1] AOU Careggi,Center for Research and Innovation of Myeloproliferative Neoplasms (CRIMM)
[2] University of Florence,Laboratorio Congiunto and Department of Experimental and Clinical Medicine
[3] University of Texas MD Anderson Cancer Center,Division of Cancer Medicine
[4] Johannes Wesling Medical Center,University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care
[5] University of Bochum,UKRUB
[6] Incyte Corporation,Centre d’Investigations Cliniques (INSERM CIC 1427)
[7] Novartis Pharmaceuticals Corporation,undefined
[8] Hôpital Saint-Louis,undefined
[9] Université Paris Diderot,undefined
来源
Annals of Hematology | 2017年 / 96卷
关键词
Allele burden; p.V617F; Polycythemia vera; Ruxolitinib;
D O I
暂无
中图分类号
学科分类号
摘要
In patients with polycythemia vera (PV), an elevated JAK2 p.V617F allele burden is associated with indicators of more severe disease (e.g., leukocytosis, splenomegaly, and increased thrombosis risk); however, correlations between allele burden reductions and clinical benefit in patients with PV have not been extensively evaluated in a randomized trial. This exploratory analysis from the multicenter, open-label, phase 3 Randomized Study of Efficacy and Safety in Polycythemia Vera With JAK Inhibitor INCB018424 Versus Best Supportive Care trial evaluated the long-term effect of ruxolitinib treatment on JAK2 p.V617F allele burden in patients with PV. Evaluable JAK2 p.V617F-positive patients randomized to ruxolitinib (n = 107) or best available therapy (BAT) who crossed over to ruxolitinib at week 32 (n = 97) had consistent JAK2 p.V617F allele burden reductions throughout the study. At all time points measured (up to weeks 208 [ruxolitinib-randomized] and 176 [ruxolitinib crossover]), mean changes from baseline over time in JAK2 p.V617F allele burden ranged from −12.2 to −40.0% (ruxolitinib-randomized) and −6.3 to −17.8% (ruxolitinib crossover). Complete or partial molecular response was observed in 3 patients (ruxolitinib-randomized, n = 2; ruxolitinib crossover, n = 1) and 54 patients (ruxolitinib-randomized, n = 33; ruxolitinib crossover, n = 20; BAT, n = 1), respectively. Among patients treated with interferon as BAT (n = 13), the mean maximal reduction in allele burden from baseline was 25.6% after crossover to ruxolitinib versus 6.6% before crossover. Collectively, the data from this exploratory analysis suggest that ruxolitinib treatment for up to 4 years provides progressive reductions in JAK2 p.V617F allele burden in patients with PV who are resistant to or intolerant of hydroxyurea. The relationship between allele burden changes and clinical outcomes in patients with PV remains unclear.
引用
收藏
页码:1113 / 1120
页数:7
相关论文
共 50 条
  • [21] Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: a systematic review and meta-analysis
    Chen, Chih-Cheng
    Chen, Justin L.
    Lin, Alex Jia-Hong
    Yu, Lennex Hsueh-Lin
    Hou, Hsin-An
    ANNALS OF HEMATOLOGY, 2024, 103 (06) : 1947 - 1965
  • [22] JAK2 V617F patients with essential thrombocythemia present with clinical features of polycythemia vera
    Zhang, Sujiang
    Qiu, Hongxia
    Fischer, Bruce S.
    Li, Weida
    Duan, Limin
    Sun, Xuemei
    Xu, Wei
    Li, Jianyong
    LEUKEMIA & LYMPHOMA, 2008, 49 (04) : 696 - 699
  • [23] A higher JAK2V617F allele burden may be a risk factor for hemorrhagic events in younger patients with polycythemia vera
    Furuya, Chiho
    Hashimoto, Yoshinori
    Morishita, Soji
    Fukuda, Yasutaka
    Inano, Tadaaki
    Ochiai, Tomonori
    Shirane, Shuichi
    Edahiro, Yoko
    Araki, Marito
    Ando, Miki
    Komatsu, Norio
    HEMATOLOGY, 2024, 29 (01)
  • [24] Dynamics of JAK2 V617F allele burden of CD34+ haematopoietic progenitor cells in patients treated with ruxolitinib
    Angona, Anna
    Alvarez-Larran, Alberto
    Bellosillo, Beatriz
    Longaron, Raquel
    Fernandez-Rodriguez, Concepcion
    Besses, Carlos
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (04) : 639 - 642
  • [25] Clinical relevance of JAK2 (V617F) mutant allele burden
    Passamonti, Francesco
    Rumi, Elisa
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (01): : 7 - 10
  • [26] The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis
    Deininger, Michael
    Radich, Jerald
    Burn, Timothy C.
    Huber, Reid
    Paranagama, Dilan
    Verstovsek, Srdan
    BLOOD, 2015, 126 (13) : 1551 - 1554
  • [27] Treatment-associated decline in JAK2V617F allele burden in polycythemia vera: What does it mean?
    Tefferi, Ayalew
    Pardanani, Animesh
    Gangat, Naseema
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (08) : 1459 - 1461
  • [28] Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia
    Shirane, Shuichi
    Araki, Marito
    Morishita, Soji
    Edahiro, Yoko
    Sunami, Yoshitaka
    Hironaka, Yumi
    Noguchi, Masaaki
    Koike, Michiaki
    Sato, Eriko
    Ohsaka, Akimichi
    Komatsu, Norio
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (02) : 148 - 153
  • [29] JAK2 V617F positive polycythemia vera in a child with neurofibromatosis type I
    Berman, Jason N.
    Greer, Wenda L.
    Archambeault, Sophie
    Loh, Mignon L.
    Riddell, Christie
    Morash, Barbara
    Dumas, Nadine
    Fernandez, Conrad V.
    Ludman, Mark D.
    PEDIATRIC BLOOD & CANCER, 2008, 51 (05) : 689 - 691
  • [30] Relation of JAK2 V617F allele burden and coronary calcium score in patients with essential thrombocythemia
    Drofenik, Ajda
    Blinc, Ales
    Mijovski, Mojca Bozic
    Pajic, Tadej
    Vrtovec, Matjaz
    Sever, Matjaz
    RADIOLOGY AND ONCOLOGY, 2024, 58 (04) : 565 - 572